Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies
- Author
- Leander Huyghe (UGent) , Alexander Van Parys (UGent) , Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Stijn De Munter (UGent) , Jennyfer Bultinck (UGent) , Lennart Zabeau (UGent) , Jeroen Hostens, An Goethals, Nele Vanderroost (UGent) , Annick Verhee (UGent) , Gilles Uze, Niko Kley, Frank Peelman (UGent) , Bart Vandekerckhove (UGent) , Peter Brouckaert (UGent) and Jan Tavernier (UGent)
- Organization
- Abstract
- Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity-on-Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF-based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T-cell infiltration leading to control or elimination of solid tumors by, respectively, CAR T cells or a combination therapy with CD8-targeted type I interferon AcTakine. Co-treatment with a CD13-targeted type II interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, safe and efficacious elimination of a broad range of tumor types becomes feasible.
- Keywords
- ISOLATED LIMB PERFUSION, ENDOTHELIAL-CELLS, AMINOPEPTIDASE N, FACTOR, RECEPTOR, FACTOR-ALPHA, IFN-GAMMA, TNF, COMBINATION, INTERFERON, EXPRESSION, cancer, interferons, neovasculature, targeted therapy, tumor necrosis, factor
Downloads
-
4296 20Huyghe.pdf
- full text
- |
- open access
- |
- |
- 2.55 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8647336
- MLA
- Huyghe, Leander, et al. “Safe Eradication of Large Established Tumors Using Neovasculature-Targeted Tumor Necrosis Factor-Based Therapies.” EMBO MOLECULAR MEDICINE, vol. 12, no. 2, 2020, doi:10.15252/emmm.201911223.
- APA
- Huyghe, L., Van Parys, A., Cauwels, A., Van Lint, S., De Munter, S., Bultinck, J., … Tavernier, J. (2020). Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO MOLECULAR MEDICINE, 12(2). https://doi.org/10.15252/emmm.201911223
- Chicago author-date
- Huyghe, Leander, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, et al. 2020. “Safe Eradication of Large Established Tumors Using Neovasculature-Targeted Tumor Necrosis Factor-Based Therapies.” EMBO MOLECULAR MEDICINE 12 (2). https://doi.org/10.15252/emmm.201911223.
- Chicago author-date (all authors)
- Huyghe, Leander, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uze, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, and Jan Tavernier. 2020. “Safe Eradication of Large Established Tumors Using Neovasculature-Targeted Tumor Necrosis Factor-Based Therapies.” EMBO MOLECULAR MEDICINE 12 (2). doi:10.15252/emmm.201911223.
- Vancouver
- 1.Huyghe L, Van Parys A, Cauwels A, Van Lint S, De Munter S, Bultinck J, et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO MOLECULAR MEDICINE. 2020;12(2).
- IEEE
- [1]L. Huyghe et al., “Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies,” EMBO MOLECULAR MEDICINE, vol. 12, no. 2, 2020.
@article{8647336,
abstract = {{Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity-on-Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF-based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T-cell infiltration leading to control or elimination of solid tumors by, respectively, CAR T cells or a combination therapy with CD8-targeted type I interferon AcTakine. Co-treatment with a CD13-targeted type II interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, safe and efficacious elimination of a broad range of tumor types becomes feasible.}},
articleno = {{e11223}},
author = {{Huyghe, Leander and Van Parys, Alexander and Cauwels, Anje and Van Lint, Sandra and De Munter, Stijn and Bultinck, Jennyfer and Zabeau, Lennart and Hostens, Jeroen and Goethals, An and Vanderroost, Nele and Verhee, Annick and Uze, Gilles and Kley, Niko and Peelman, Frank and Vandekerckhove, Bart and Brouckaert, Peter and Tavernier, Jan}},
issn = {{1757-4676}},
journal = {{EMBO MOLECULAR MEDICINE}},
keywords = {{ISOLATED LIMB PERFUSION,ENDOTHELIAL-CELLS,AMINOPEPTIDASE N,FACTOR,RECEPTOR,FACTOR-ALPHA,IFN-GAMMA,TNF,COMBINATION,INTERFERON,EXPRESSION,cancer,interferons,neovasculature,targeted therapy,tumor necrosis,factor}},
language = {{eng}},
number = {{2}},
pages = {{15}},
title = {{Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies}},
url = {{http://doi.org/10.15252/emmm.201911223}},
volume = {{12}},
year = {{2020}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: